In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 28, No. 12 ( 2013-12), p. 1829-1833
Abstract:
Infliximab is currently used for the treatment of moderate‐to‐severe ulcerative colitis ( UC ) with an inadequate response to conventional agents. The efficacy and safety of infliximab in K orean patients with UC were assessed. Methods This was a retrospective multicenter study including all adult patients who received at least one infliximab infusion for UC . Short‐ and long‐term clinical outcomes and adverse events of infliximab therapy were evaluated, and predictors of response were identified. Results A total of 134 UC patients were included. The indications for infliximab therapy were acute severe UC in 28%, steroid‐dependency in 38%, and steroid‐refractoriness in 33%, respectively. The rates of clinical response and remission were 87% and 45% at week 8. In multivariate analysis, we found significant predictors of clinical remission at week 8: immunomodulator‐naïve (odds ratio [ OR ] = 4.89, 95% confidence interval [ CI ]: 1.44–16.66, P = 0.01), hemoglobin ≥ 11.5 g/ dL ( OR = 4.47, 95% CI : 1.48–13.45, P = 0.008), C ‐reactive protein ≥ 3 mg/ dL ( OR = 4.77, 95% CI : 1.43–15.94, P = 0.01), and response at week 2 ( OR = 20.54, 95% CI : 2.40–175.71, P = 0.006). Long‐term clinical response and remission rates were 71% and 52%, respectively, and mucosal healing was the only factor influencing long‐term response. Adverse events related to infliximab occurred in 15% of patients, and most of them were mild and transient. Conclusions Infliximab is effective and safe in the treatment of active UC in K orea. No history of previous immunomodulator use and high baseline C ‐reactive protein are independent predictors of good response.
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2013.28.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2006782-3
Bookmarklink